ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy ACAD?
Source: seekingalpha
- Revenue Growth: ACADIA reported total revenue of $268 million in Q1 2026, reflecting an 11% increase compared to the previous year, indicating stable performance in the market, particularly driven by strong DAYBUE sales.
- DAYBUE STIX Launch: The DAYBUE STIX was broadly launched across the U.S., achieving $101 million in sales in the first quarter, a 20% increase year-over-year, demonstrating significant progress in attracting new patients and re-engaging previously discontinued ones.
- 2026 Financial Guidance: Management reaffirmed its revenue guidance for 2026, projecting total revenues between $1.22 billion and $1.28 billion, emphasizing that upcoming results from the remlifanserin Phase II trial will be a key near-term catalyst expected to be shared between August and October.
- Leadership Transition: R&D head Elizabeth Thompson announced her retirement by year-end for personal reasons, yet she remains fully engaged in advancing the company's pipeline, ensuring business continuity during this transition period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACAD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 22.400
Low
23.00
Averages
31.17
High
40.00
Current: 22.400
Low
23.00
Averages
31.17
High
40.00
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: ACADIA reported total revenue of $268 million in Q1 2026, reflecting an 11% increase compared to the previous year, indicating stable performance in the market, particularly driven by strong DAYBUE sales.
- DAYBUE STIX Launch: The DAYBUE STIX was broadly launched across the U.S., achieving $101 million in sales in the first quarter, a 20% increase year-over-year, demonstrating significant progress in attracting new patients and re-engaging previously discontinued ones.
- 2026 Financial Guidance: Management reaffirmed its revenue guidance for 2026, projecting total revenues between $1.22 billion and $1.28 billion, emphasizing that upcoming results from the remlifanserin Phase II trial will be a key near-term catalyst expected to be shared between August and October.
- Leadership Transition: R&D head Elizabeth Thompson announced her retirement by year-end for personal reasons, yet she remains fully engaged in advancing the company's pipeline, ensuring business continuity during this transition period.
See More
Acadia (ACAD) Q1 2026 Earnings Transcript
See More
Acadia Pharmaceuticals to Present Multiple Data at AAN Annual Meeting
- Data Presentation: Acadia Pharmaceuticals will present multiple original data sets at the 2026 American Academy of Neurology Annual Meeting, reflecting the company's ongoing commitment to research in neurological diseases.
- LOTUS Study Findings: The company will share real-world data on DAYBUE® (trofinetide) in adults with Rett syndrome, highlighting its benefits and tolerability in clinical practice, which may enhance market acceptance of the drug.
- Parkinson's Disease Psychosis Analysis: Acadia will also present exploratory analyses of NUPLAZID® (pimavanserin) treatment response trajectories in Parkinson's disease psychosis patients, revealing the impact of baseline sleep disturbances on treatment outcomes, potentially informing personalized treatment approaches.
- ACP-711 Development Progress: The company will debut translational research and pharmacokinetic data for ACP-711, supporting its development for essential tremor, showcasing Acadia's forward-looking strategy in neurological drug development.
See More
Acadia Launches DAYBUE STIX Powder for Rett Syndrome Treatment
- New Drug Launch: Acadia Pharmaceuticals announced that DAYBUE STIX (trofinetide) powder formulation is now broadly available in the U.S. for treating Rett syndrome in patients aged two and older, marking a significant innovation in the neurological disease sector.
- High Patient Satisfaction: Initial feedback indicates that over 80% of early users reported satisfaction with DAYBUE STIX, highlighting its advantages in flexibility and portability, which may enhance the medication experience for patients.
- Expert Consensus Support: A steering group of experts from the International Rett Syndrome Foundation has recognized trofinetide oral solution as part of the standard of care, emphasizing the importance of individualized decision-making to optimize treatment outcomes for patients and families, further solidifying DAYBUE STIX's clinical position.
- Diverse Administration Options: DAYBUE STIX can be mixed with various water-based liquids, providing personalized taste options that cater to the unique needs of patients and caregivers, aligning with modern healthcare's patient-centered treatment philosophy.
See More
BofA Upgrades Acadia Pharmaceuticals to Buy Amid Price Pullback
- Rating Upgrade: BofA Securities has upgraded Acadia Pharmaceuticals (ACAD) from neutral to buy, citing that the company's fundamentals remain intact despite a 25% pullback in share price since the beginning of the year, which is attributed mainly to macro factors.
- Price Target Maintained: The bank maintains a price target of $29 for Acadia, which implies approximately 38% upside based on the March 24 close, reflecting confidence in the company's future performance.
- Sales Forecast: Analysts project that steady sales of Nuplazid (pimavanserin) will help mitigate further downside risks, estimating peak sales of $888 million by 2029, indicating strong market potential for the product.
- Pipeline Opportunity: While the company estimates its pipeline could offer an $11 billion opportunity, BofA believes this figure is currently discounted and may provide upside, reiterating a 40% likelihood of success for remlifanserin with projected peak sales of $2.1 billion in 2038.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: ACADIA reported total revenue of $268 million in Q1 2026, reflecting an 11% increase compared to the previous year, indicating stable performance in the market, particularly driven by strong DAYBUE sales.
- DAYBUE STIX Launch: The DAYBUE STIX was broadly launched across the U.S., achieving $101 million in sales in the first quarter, a 20% increase year-over-year, demonstrating significant progress in attracting new patients and re-engaging previously discontinued ones.
- 2026 Financial Guidance: Management reaffirmed its revenue guidance for 2026, projecting total revenues between $1.22 billion and $1.28 billion, emphasizing that upcoming results from the remlifanserin Phase II trial will be a key near-term catalyst expected to be shared between August and October.
- Leadership Transition: R&D head Elizabeth Thompson announced her retirement by year-end for personal reasons, yet she remains fully engaged in advancing the company's pipeline, ensuring business continuity during this transition period.
See More
Acadia (ACAD) Q1 2026 Earnings Transcript
See More
Acadia Pharmaceuticals to Present Multiple Data at AAN Annual Meeting
- Data Presentation: Acadia Pharmaceuticals will present multiple original data sets at the 2026 American Academy of Neurology Annual Meeting, reflecting the company's ongoing commitment to research in neurological diseases.
- LOTUS Study Findings: The company will share real-world data on DAYBUE® (trofinetide) in adults with Rett syndrome, highlighting its benefits and tolerability in clinical practice, which may enhance market acceptance of the drug.
- Parkinson's Disease Psychosis Analysis: Acadia will also present exploratory analyses of NUPLAZID® (pimavanserin) treatment response trajectories in Parkinson's disease psychosis patients, revealing the impact of baseline sleep disturbances on treatment outcomes, potentially informing personalized treatment approaches.
- ACP-711 Development Progress: The company will debut translational research and pharmacokinetic data for ACP-711, supporting its development for essential tremor, showcasing Acadia's forward-looking strategy in neurological drug development.
See More
Acadia Launches DAYBUE STIX Powder for Rett Syndrome Treatment
- New Drug Launch: Acadia Pharmaceuticals announced that DAYBUE STIX (trofinetide) powder formulation is now broadly available in the U.S. for treating Rett syndrome in patients aged two and older, marking a significant innovation in the neurological disease sector.
- High Patient Satisfaction: Initial feedback indicates that over 80% of early users reported satisfaction with DAYBUE STIX, highlighting its advantages in flexibility and portability, which may enhance the medication experience for patients.
- Expert Consensus Support: A steering group of experts from the International Rett Syndrome Foundation has recognized trofinetide oral solution as part of the standard of care, emphasizing the importance of individualized decision-making to optimize treatment outcomes for patients and families, further solidifying DAYBUE STIX's clinical position.
- Diverse Administration Options: DAYBUE STIX can be mixed with various water-based liquids, providing personalized taste options that cater to the unique needs of patients and caregivers, aligning with modern healthcare's patient-centered treatment philosophy.
See More
BofA Upgrades Acadia Pharmaceuticals to Buy Amid Price Pullback
- Rating Upgrade: BofA Securities has upgraded Acadia Pharmaceuticals (ACAD) from neutral to buy, citing that the company's fundamentals remain intact despite a 25% pullback in share price since the beginning of the year, which is attributed mainly to macro factors.
- Price Target Maintained: The bank maintains a price target of $29 for Acadia, which implies approximately 38% upside based on the March 24 close, reflecting confidence in the company's future performance.
- Sales Forecast: Analysts project that steady sales of Nuplazid (pimavanserin) will help mitigate further downside risks, estimating peak sales of $888 million by 2029, indicating strong market potential for the product.
- Pipeline Opportunity: While the company estimates its pipeline could offer an $11 billion opportunity, BofA believes this figure is currently discounted and may provide upside, reiterating a 40% likelihood of success for remlifanserin with projected peak sales of $2.1 billion in 2038.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
